Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model

Some European countries decided to include human papillomavirus (HPV) vaccines in national immunization schedules. In order to help decision makers choose the best vaccination policy for females, a decisional model has been developed. The study was performed from the National Health Service perspect...

Full description

Saved in:
Bibliographic Details
Published in:Epidemiology and infection 2009-06, Vol.137 (6), p.794-802
Main Authors: GASPARINI, R., AMICIZIA, D., MANFREDI, P., ANSALDI, F., LUCIONI, C., GALLELLI, G., PANATTO, D.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age
Age Distribution
Biological and medical sciences
Cervical cancer
Child
Cost analysis
Cost effectiveness analysis
Cost efficiency
Decision Making
Decision Trees
Decisional model
Dosage
Drug Administration Schedule
Epidemiology
Female
Fundamental and applied biological sciences. Psychology
Genotypes
Health Policy - economics
HPV
Human papillomavirus
Humans
Infections
Microbiology
Miscellaneous
Models, Theoretical
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - immunology
Sensitivity analysis
Vaccination
Vaccination - economics
Vaccination - methods
vaccination policies
Vaccines
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Some European countries decided to include human papillomavirus (HPV) vaccines in national immunization schedules. In order to help decision makers choose the best vaccination policy for females, a decisional model has been developed. The study was performed from the National Health Service perspective. Several hypotheses of multi-cohort vaccination policies were compared. 'Potentially avoidable infections' were chosen as the outcome. The model envisioned a short-term scenario (2008-2011). The best policy was that of vaccinating 12-year-olds and, a year later, those aged 14-16 years; the most expensive strategy was that of vaccinating 12-year-old females and, after 1 year, vaccinating those aged 15, 18 and 25 years. The sensitivity analysis showed that coverage rate has a great effect on the cost of avoidable infections. The study offers stake-holders an important datum-point for the choice of the best HPV policy vaccination in the short term. Indeed, it could generate interesting savings for the National Health Service and a rapid HPV immunization of young girls.
ISSN:0950-2688
1469-4409
DOI:10.1017/S0950268808001441